In the BEAM trial, was magnesium sulfate (MgSO₄) continued after delivery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

BEAM Trial Magnesium Sulfate Protocol After Delivery

In the BEAM trial, magnesium sulfate was continued after delivery for up to 24 hours postpartum. 1

BEAM Trial Protocol Specifics

The BEAM (Beneficial Effects of Antenatal Magnesium) trial used a specific dosing regimen that included postpartum continuation:

  • Loading dose: 6 g IV initially
  • Maintenance dose: 2 g/hour continuous infusion
  • Duration: Continued for up to 24 hours total (including postpartum period)

This protocol differs from other major trials and represents one of the higher-dose regimens studied for fetal neuroprotection 1. The BEAM trial's approach of continuing magnesium sulfate postpartum aligns with standard eclampsia prophylaxis protocols, where the drug is maintained through the immediate postpartum period when seizure risk remains elevated.

Current Guideline Recommendations

The ISSHP (International Society for the Study of Hypertension in Pregnancy) recommends continuing magnesium sulfate for 24 hours postpartum when used for preeclampsia/eclampsia prophylaxis 2. This recommendation acknowledges:

  • Eclampsia can occur postpartum
  • The known incidence of postpartum eclampsia justifies continued prophylaxis
  • One Latin American study found no additional benefit of continuing magnesium beyond delivery in women who received ≥8 g before delivery, but guidelines recommend 24-hour continuation until further studies confirm these findings in other populations 2

Clinical Context

The BEAM trial specifically studied magnesium sulfate for fetal neuroprotection in anticipated preterm delivery <32 weeks, not for maternal seizure prophylaxis 1, 3. However, the trial protocol maintained the infusion postpartum, consistent with standard obstetric practice for magnesium administration.

Important distinction: When magnesium sulfate is used solely for fetal neuroprotection (not for preeclampsia), some protocols use only a bolus dose or shorter infusions. The BEAM trial's extended protocol through 24 hours postpartum was part of their specific research design 1.

References

Research

The role of magnesium sulfate (MgSO4) in fetal neuroprotection.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2021

Research

Impact of dosing schedule on uptake of neuroprotective magnesium sulfate.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.